A Phase 3 trial comparing a combination therapy containing 'Rilvegostomig (Trial name: AZD2936),' AstraZeneca's bispecific antibody gathering attention as the next-generation medicine, to 'Keytruda (pembrolizumab),' a type of immunotherapy drug used to treat cancer, will be conducted in South Korea.

The Ministry of Food and Drug Safety (MFDS) has approved a Phase 3, randomized, double-blind, multicenter, and global ARTEMIDE-Lung03 study, evaluating Rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous PD-L1-positive metastatic non-small cell lung cancer (NSCLC).

Rilvegostomig is a PD-1/TIGIT target